Research Highlights
Nature Biotechnology 36, 150 (2018).
doi:10.1038/nbt.4076 (Source: Nature Biotechnology)
Source: Nature Biotechnology - February 6, 2018 Category: Biotechnology Tags: News and Views Source Type: research
Making brain proteomics true to type
Nature Biotechnology 36, 149 (2018).
doi:10.1038/nbt.4077
Authors: Rashaun S Wilson & Angus C Nairn
Two independent but related strategies use unnatural amino acid incorporation to enable in vivo cell-type-specific proteomics in the mouse brain. (Source: Nature Biotechnology)
Source: Nature Biotechnology - February 6, 2018 Category: Biotechnology Authors: Rashaun S Wilson Angus C Nairn Tags: News and Views Source Type: research
PrePAIRing Cas9s for screening success
Nature Biotechnology 36, 147 (2018).
doi:10.1038/nbt.4075
Authors: Zhuo Zhou & Wensheng Wei
Orthogonal CRISPR–Cas9 nucleases enable more efficient high-throughput screens for deciphering genetic interactions. (Source: Nature Biotechnology)
Source: Nature Biotechnology - February 6, 2018 Category: Biotechnology Authors: Zhuo Zhou Wensheng Wei Tags: News and Views Source Type: research
Recent patents in neoantigens and neoepitopes
Nature Biotechnology 36, 146 (2018).
doi:10.1038/nbt.4083 (Source: Nature Biotechnology)
Source: Nature Biotechnology - February 6, 2018 Category: Biotechnology Tags: Feature Source Type: research
Tertiary patenting on drug – device combination products in the United States
Nature Biotechnology 36, 142 (2018).
doi:10.1038/nbt.4078
Authors: Reed F Beall & Aaron S Kesselheim
Drug–device combination products are becoming increasingly prevalent, with many lasting years beyond the expiration date of primary and secondary patents on the drug itself. (Source: Nature Biotechnology)
Source: Nature Biotechnology - February 6, 2018 Category: Biotechnology Authors: Reed F Beall Aaron S Kesselheim Tags: Feature Source Type: research
An alternative proposal to the destruction of abandoned human embryos
Nature Biotechnology 36, 139 (2018).
doi:10.1038/nbt.4070
Authors: Norbert Gleicher & Arthur L Caplan (Source: Nature Biotechnology)
Source: Nature Biotechnology - February 6, 2018 Category: Biotechnology Authors: Norbert Gleicher Arthur L Caplan Tags: Opinion and Comment Source Type: research
Rationalizing governance of genetically modified products in developing countries
Nature Biotechnology 36, 137 (2018).
doi:10.1038/nbt.4069
Authors: Ademola A Adenle, E Jane Morris, Denis J Murphy, Peter W B Phillips, Eduardo Trigo, Peter Kearns, Yun-He Li, Hector Quemada, José Falck-Zepeda & John Komen (Source: Nature Biotechnology)
Source: Nature Biotechnology - February 6, 2018 Category: Biotechnology Authors: Ademola A Adenle E Jane Morris Denis J Murphy Peter W B Phillips Eduardo Trigo Peter Kearns Yun-He Li Hector Quemada Jos é Falck-Zepeda John Komen Tags: Opinion and Comment Source Type: research
Drug pipeline: 4Q17
Nature Biotechnology 36, 130 (2018).
doi:10.1038/nbt.4073
Author: Laura DeFrancesco (Source: Nature Biotechnology)
Source: Nature Biotechnology - February 6, 2018 Category: Biotechnology Authors: Laura DeFrancesco Tags: News Source Type: research
2017 — venture funding goes into overdrive
Nature Biotechnology 36, 129 (2018).
doi:10.1038/nbt.4081
Author: Laura DeFrancesco (Source: Nature Biotechnology)
Source: Nature Biotechnology - February 6, 2018 Category: Biotechnology Authors: Laura DeFrancesco Tags: News Source Type: research
US tax reform may jeopardize orphans
Nature Biotechnology 36, 128 (2018).
doi:10.1038/nbt0218-128
Author: Chris Morrison (Source: Nature Biotechnology)
Source: Nature Biotechnology - February 6, 2018 Category: Biotechnology Authors: Chris Morrison Tags: News Source Type: research
Around the world in a month
Nature Biotechnology 36, 127 (2018).
doi:10.1038/nbt0218-127 (Source: Nature Biotechnology)
Source: Nature Biotechnology - February 6, 2018 Category: Biotechnology Tags: News Source Type: research
California voters and CIRM — will lightning strike twice?
Nature Biotechnology 36, 126 (2018).
doi:10.1038/nbt0218-126
Author: Laura DeFrancesco (Source: Nature Biotechnology)
Source: Nature Biotechnology - February 6, 2018 Category: Biotechnology Authors: Laura DeFrancesco Tags: News Source Type: research
Approval of first tumor gene panel sends shockwaves through labs
Nature Biotechnology 36, 124 (2018).
doi:10.1038/nbt0218-124
Author: Mark Ratner (Source: Nature Biotechnology)
Source: Nature Biotechnology - February 6, 2018 Category: Biotechnology Authors: Mark Ratner Tags: News Source Type: research
Roche pays $1.7 billion to target tumors' genetic signatures
Nature Biotechnology 36, 123 (2018).
doi:10.1038/nbt0218-123 (Source: Nature Biotechnology)
Source: Nature Biotechnology - February 6, 2018 Category: Biotechnology Tags: News Source Type: research
Spark's gene therapy price tag: $850,000
Nature Biotechnology 36, 122 (2018).
doi:10.1038/nbt0218-122 (Source: Nature Biotechnology)
Source: Nature Biotechnology - February 6, 2018 Category: Biotechnology Tags: News Source Type: research
